These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29900654)

  • 1. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
    Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
    Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A micro-elimination approach to addressing hepatitis C in Turkey.
    Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
    BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. Commentary.
    Kondili LA; Aghemo A; Andreoni M
    Ann Ist Super Sanita; 2021; 57(3):201-204. PubMed ID: 34554113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; De Michina A; Merolla R; Marrocco W; Craxì A
    BMC Infect Dis; 2022 Jan; 22(1):58. PubMed ID: 35038987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; Roscini AS; Merolla R; Marrocco W; Craxì A
    Epidemics; 2021 Mar; 34():100442. PubMed ID: 33607538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is global elimination of HCV realistic?
    Calvaruso V; Petta S; Craxì A
    Liver Int; 2018 Feb; 38 Suppl 1():40-46. PubMed ID: 29427499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
    PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
    Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
    J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
    J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
    PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria.
    Schwarz C; Bauer D; Dorn L; Jachs M; Hartl L; Chromy D; Weseslindtner L; Pfisterer N; Hennlich B; Stückler A; Strassl R; Voill-Glaninger A; Hübl W; Willheim M; Köhrer K; Jansen-Skoupy S; Tomez S; Krugluger W; Madl C; Schwarz M; Balcar L; Semmler G; Brinkmann L; Burghart L; Antonitsch L; Weidinger G; Riedl F; Laferl H; Kurteva V; Traugott M; Hind J; Wenisch C; Aburaia A; Sebesta C; Schmid D; Rothweiler S; Remetic J; Gschwantler M; Maieron A; Reiberger T
    Wien Klin Wochenschr; 2024 May; 136(9-10):278-288. PubMed ID: 37773541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    Shiha G; Soliman R; Mikhail NNH; Easterbrook P
    J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forecasting the long-term impact of COVID-19 on hepatitis C elimination plans in Italy: A mathematical modelling approach.
    Kondili LA; Andreoni M; Aghemo A; Mastroianni CM; Merolla R; Gallinaro V; D'Offizi G; Craxì A
    Liver Int; 2023 Dec; 43(12):2615-2624. PubMed ID: 37735959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.